Document is current
Any future updates will be listed below
-
Authors
Jordà, Paloma https://orcid.org/0000-0002-9236-1713
Lai, Yiwei
Jeuken, Amélie
Lemieux Perreault, Louis-Philippe https://orcid.org/0000-0001-7423-0958
Goulet, Elisabeth
Lahrouchi, Najim
Nozza, Anna
Tanck, Michael W.
Guerra, Peter
Cadrin-Tourigny, Julia
de Denus, Simon
Bezzina, Connie R.
Lettre, Guillaume
Busseuil, David
Dubé, Marie-Pierre https://orcid.org/0000-0001-8442-4393
Tardif, Jean-Claude https://orcid.org/0000-0002-8200-8983
Tadros, Rafik https://orcid.org/0000-0002-1472-0258
- License Information
-
More Information
Article History
Received: 13 September 2024
Accepted: 11 July 2025
First Online: 29 September 2025
Competing interests
: S.d-D. reports grants outside the submitted work from AstraZeneca and RMS/Dalcor. M.-P.D. has patents unrelated to this work: “Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events” issued to Dalcor, no royalties received; “Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent” issued to Dalcor, no royalties received; and “Methods for using low dose colchicine after myocardial infarction”, assigned to the Montreal Heart Institute. M.-P.D. reports equity interest in Dalcor, unrelated to this work. Jean-Claude T. has received research grants from Amarin, AstraZeneca, Ceapro, DalCor, Esperion, Ionis, Novartis, Pfizer and RegenXBio; honoraria from AstraZeneca, DalCor, HLS Therapeutics, Pendopharm and Pfizer; holds a minor equity interest in DalCor; and is an author of a patent on pharmacogenomics-guided CETP inhibition. R.T. receives research support from BMS Canada.
